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Abstract
Background: The risk of developing diabetes mellitus (DM) during treatment with high-
dose glucocorticoids is unknown and monitoring of glucose is random in many settings.
Objective: To determine incidence of and risk factors for induction of DM during  
high-dose glucocorticoid therapy of metastatic spinal cord compression (MSCC) 
in patients referred to radiotherapy. Furthermore, to describe the time course of 
development of DM.
Subjects and methods: 140 patients were recruited (131 were included in the analysis) 
with MSCC receiving high-dose glucocorticoid ≥100 mg prednisolone per day were 
included in a prospective, observational cohort study. The primary endpoint was 
development of DM defined by two or more plasma glucose values ≥11.1 mmol/L. Plasma 
glucose was monitored on a daily basis for 12 days during radiotherapy.
Results: Fifty-six of the patients (43%; 95% CI 35–52%) were diagnosed with DM based 
on plasma glucose measurements during the study period. Sixteen patients, 12% (95% 
CI 6–18%), were treated with insulin. At multivariate analysis, only high baseline HbA1c 
predicted the development of insulin-treated DM. An HbA1c-value <39 mmol/mol was 
associated with a negative predictive value of 96% for not developing DM needing 
treatment with insulin. The diagnosis of diabetes with need for insulin treatment was 
made within 7 days in 14 of the 16 (88%; 95% CI 72–100%) patients.
Conclusion: The risk of developing DM during treatment with high-dose glucocorticoids 
in patients with MSCC referred to radiotherapy is high in the first treatment week. Only 
referral HbA1c predicts the development of DM.
Introduction
In patients with malignant disease, glucocorticoids are 
widely used on various indications. High-dose treatment 
is given as part of chemotherapy regimens and for treating 
oedema associated with metastatic spinal cord compression 
(MSCC) and brain tumours. Diabetes mellitus (DM) is a 
well-known metabolic side effect from treatment with 
glucocorticoids. The diabetogenic effect is mainly a result 
of insulin resistance in muscle and fatty tissue, increased 
production of glucose from the liver, and eventually also 
impaired beta-cell function (1). Hyperglycaemic symptoms 
may impair patients’ well-being and with more severe 
hyperglycemia, they may become catabolic and more 
susceptible to infections and impaired wound healing. 
Undiagnosed or untreated DM may ultimately develop 
into potentially fatal hyperglycaemic hyperosmolar 
state (2, 3). Furthermore, glucocorticoid-induced 
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hyperglycemia during chemotherapy has been associated 
with a poorer prognosis such as a shorter remission period, 
a shorter median survival and a higher rate of side effects 
to the antineoplastic therapy (4).
Despite the potential clinical significance, there 
are only scarce data on incidence of and risk factors for 
development of DM during high-dose glucocorticoid 
therapy in cancer patients. Thus, only two retrospective 
studies both hampered by lack of systematic screening 
and lack of data on the actual screening intensity have 
reported the incidence in the range from 13% to 37% 
(4, 5). In these studies, development of DM during 
glucocorticoid therapy was inconsistently associated 
with age, thrombocytopenia and dose of glucocorticoid. 
Furthermore, the time course for development of 
glucocorticoid-induced DM is not well described.
The current lack of knowledge in the field is reflected 
by the fact that there are no generally accepted guidelines 
for screening for and handling of DM occurring during 
treatment with glucocorticoids. Accordingly, The Joint 
British Diabetes Societies for Inpatient Care and the 
American Endocrine Society have made each their 
suggestions, both based on a low level of evidence (6, 7).
Therefore, we conducted a prospective, observational 
study in order to determine the incidence and the 
time course of development of DM in patients without 
previously known DM with MSCC receiving high-
dose glucocorticoid therapy. We also aimed to identify 
potential risk factors.
Subjects and methods
Design
From May 2013 to December 2014, we conducted 
a prospective, observational cohort study including 
patients from the Department of Radiation Oncology at 
Rigshospitalet, Copenhagen. Patients with a tentative 
diagnosis of MSCC are referred to the unit 24 h a day 
7 days a week from an area with approximately 2.4 million 
inhabitants. If the diagnosis of MSCC is confirmed, the 
patient is offered either radiotherapy alone or surgical 
decompression followed by radiotherapy. High-dose 
glucocorticoid therapy has been proven beneficial as an 
adjunct to radiotherapy (8) and is most often initialised at 
the local hospital, alternatively prescribed at the first visit 
at Rigshospitalet. The study was approved by The National 
Committee on Health Research Ethics (file number H-4-
2012-004) and reported to the Danish Data Protection 
Agency (file number HIH-2011-22). All participants gave 
their written informed consent.
Subjects
Patients with a histologically confirmed cancer diagnosis 
were eligible for inclusion if they were aged 18 years or 
more, were diagnosed with MSCC, treated with ≥100 mg 
prednisolone daily and were referred to radiotherapy 
treatment with 30 Grey in 10 fractions. Known DM was 
the only exclusion criterion. We chose not to exclude 
patients due to other reasons since we wanted to do a 
‘real-life’ study.
Clinical and laboratory data
At the time of inclusion, we obtained information on 
height and body weight, medical history, DM in first- and 
second-degree relatives, tobacco and alcohol consumption 
and medications data. Venous blood samples were collected 
for analysis of HbA1c, C-peptide, lipids and plasma 
glucose. HbA1c was measured using a commercial liquid 
chromatography analysis, normal range <48 mmol/mol. 
Other analyses were done by standard methods. 
Performance status (PS) was assessed using the toxicity 
and response criteria of the Eastern Cooperative Oncology 
Group (ECOG) (9). On the last day of radiotherapy, venous 
blood samples for measurement of HbA1c, C-peptide, 
lipids and plasma glucose were repeated. The dose of 
prednisolone was registered on a daily basis.
Screening procedure
The subsequent 12  days after inclusion one to four 
capillary blood glucose measurements daily were 
performed using a Medisense Precision XceedPro 
Glucosemeter (Abbott Diabetes Care). In inpatients, we 
aimed at three measurements a day in their local hospital 
and one measurement in the Section of Radiotherapy, 
while outpatients had one measurement in conjunction 
with radiotherapy. The time of the daily glucose 
measurements depended on local guidelines and the 
scheduled radiotherapy.
Endpoints
The primary endpoint was DM defined as two random 
plasma glucose measurements ≥11.1 mmol/L. The WHO 
diagnostic criteria for DM are fasting plasma glucose 
≥7.0 mmol/L or 2-h plasma glucose ≥11.1 mmol/L, but as 
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neither fasting glucose measurements nor an oral glucose 
tolerance test was feasible in the setting of this study, we 
chose the above mentioned definition (10). Due to the 
short time of observation, DM defined by HbA1c was 
not considered feasible. The secondary endpoint was the 
number of patients, who started treatment with insulin. 
There were no study instructions about the initiation 
of insulin treatment. This decision was taken only by 
the doctors at the department to which the patient was 
admitted. Patients were defined as having insulin-treated 
DM from their first injection of insulin.
Statistics
A sample size of 140 participants was calculated from 
an expected prevalence of DM of 15% with an accuracy 
of ±5%. Standard statistical tests were used to compare 
demographic and diabetes-related parameters. To identify 
risk factors for developing DM requiring insulin treatment, 
univariate and multivariate logistic regression analyses 
were done. Known risk factors for type 2 diabetes (BMI, sex, 
age, having a first- or second-degree relative with DM) and 
variables associated with developing DM in the univariate 
analysis (P < 0.15) were included in the multivariate 
analysis. A P-value (two sided) ≤0.05 was considered 
statistically significant. Data were analysed using the SPSS 
software application (version 19.0 and 22.0).
Results
Recruitment/response
Of 324 patients assessed for eligibility, 140 were recruited 
(43%) and 131 were included in the analysis (Fig. 1).
We followed 109 (83%) of the patients for 12 days, 
and 22 patients (17%) for 6–11 days as calculated from the 
day of prednisolone initiation until the last blood glucose 
measurement.
The median number of plasma glucose measurements 
per patient was 24 (IQR 15–32) in fully hospitalised 
patients, 11 (IQR 8–17) in patients partially hospitalised 
and 8 (IQR 7–9) in outpatients.
There was no association between the number of 
blood glucose measurements and the detection of DM.
Characteristics of the sample
Baseline characteristics of the participants are presented 
in Table  1. The study population resembles the overall 
population of MSCC patients referred to Rigshospitalet 
with regard to sex, age and oncological diagnosis (11).
Incidence and time course of development 
of diabetes
During follow-up a total of 56 patients (43%; 95% CI 
35–52%) presented plasma glucose values diagnostic of 
DM. Sixteen patients developing DM were treated with 
insulin, 12% (95% CI 6–18%) of the total population and 
29% (95% CI 21–37%) of the patients with a diagnosis of 
DM (Table 1).
The incidence of DM left untreated rose steadily 
throughout the observation period. In contrast, the need 
for insulin therapy was decided within 7  days after the 
diagnosis of DM in 14 of the 16 (88%; 95% CI 72–100%) 
insulin-treated patients (Fig. 2).
In Fig. 3, the plasma glucose values are plotted against 
time of the day according to groups of DM status. Plasma 
glucose was highest in the afternoon in all the three 
groups of patients. In a mixed model performed separately 
for each group (no DM, untreated DM and insulin-treated 
DM) the level of glucose depended on time of day in all 
three groups (P < 0.001 in all groups).
Baseline HbA1c as predictor for insulin-treated 
with insulin
Six of the 131 patients (5%; 95% CI 1–9%) had a slightly 
elevated HbA1c value at baseline (49–57 mmol/mol). 
Of these, 3 developed insulin-treated DM, 3 developed 
Assessed for eligibility (n=324)
Excluded (n=184)
Not meeng inclusion criteria (n=100)
Known diabetes (n=29)
Declined to partcipate (n=8)
Other reasons (n=47)
Excluded from analysis (n=9)
Changes in treatment plan (n=7)
Known diabetes (n=2)
Analysed (n=131)
Included (n=140)
Figure 1
Consort diagram.
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untreated DM and 1 did not develop DM. Further, one 
patient had overt unknown DM (HbA1c = 79 mmol/mol) at 
baseline and needed insulin therapy. A high baseline HbA1c 
was associated with increased risk of glucocorticoid-induced 
DM both in univariate and multivariate logistic regression 
analyses (Table  2). The American Diabetes Association 
defines an HbA1c value ≥39 mmol/mol as diagnostic for 
prediabetes (12). Using this cut-off as a predictive value for 
developing glucocorticoid-induced DM treated with insulin, 
the sensitivity was 86% (95% CI: 67–100), the specificity 
Table 1 Baseline characteristics of the entire cohort and according to outcome.
 
Variable
 
All
 
No diabetes
 
Untreated diabetes
Diabetes treated 
with insulin
N (%) 131 (100) 75 (57) 40 (31) 16 (12)
Female sex (%) 42 43 45 31
Age (years), min–max 68 (46–88) 68 (48–88) 68 (46–87) 69 (50–86)
BMI (kg/m2), min–max 25 (14–44) 25 (15–44)
N = 73
24 (14–31)
N = 38
25 (18–33)
N = 15
Performance status (%)
 0 6 (4) 6 (8) 0 0 (0)
 1 52 (40) 36 (48) 13 (32) 3 (19)
 2 44 (34) 18 (24) 19 (48) 7 (44)
 3 29 (22) 15 (20) 8 (20) 6 (37)
Primary tumour (%)
 Lung 36 (27) 22 (29) 10 (25) 4 (25)
 Breast 25 (19) 16 (21) 7 (17) 2 (13)
 Prostate 31 (24) 14 (19) 12 (30) 5 (31)
 Others 39 (30) 23 (31) 11 (28) 5 (31)
 Brain metastases (%) 5 (4) 4 (5) 0 1 (6)
 Lung metastases (%) 51 (39) 35 (47) 13 (33) 3 (19)
 Liver metastases (%) 30 (23) 16 (21) 9 (23) 5 (31)
 Bone metastases (%) 129 (99) 74 (99) 39 (98) 16 (100)
 Pancreatic metastases (%) 0 0 0 0
 Alcohol abuse now or earlier (%) 26 (20) 14 (19) 9 (23) 3 (19)
 Smoking, now or earlier (%) 88 (67) 52 (69) 27 (68) 9 (56)
 Antihypertensive therapy (%) 52 (40) 30 (40) 16 (40) 6 (38)
 Lipid lowering therapy (%) 27 (21) 19 (25) 6 (15) 2 (13)
 Atheroschlerosis (%) 17 (13) 10 (13) 4 (10) 3 (19)
 Liver disease (%) 3 (2) 7 (9) 1 (3) 0
 Thyroid disease (%) 11 (8) 7 (9) 3 (8) 1 (6)
 Pancreatic disease (%) 2 (2) 1 (1) 1 (3) 0
Hospitalisation or not
 Outpatient 56 (43) 41 (55) 15 (38) 0
 Inpatient 53 (40) 21 (28) 19 (47) 13 (81)
 Alternating 22 (17) 13 (17) 6 (15) 3 (19)
 Prednisolone start dose (mg), mean (min–max) 261 (100–2500) 234 (100–350) 307 (100–2500) 275 (150–300)
 Cumulated dose of prednisolone (mg), mean 
(min–max)
2919 (1000–6750) 2835 (1200–3650) 3040 (1000–6750) 2966 (1400–3600)
 Daily prednisolone dose (mg), mean (min–max) 247 (83–563) 240 (100–304) 255 (83–563) 259 (150–300)
Previous glucocorticoid treatment (%)
 None 75 (57) 43 (57) 23 (58) 9 (56)
 In relation to chemotherapy 26 (20) 17 (23) 6 (15) 3 (19)
 Earlier from time to time 16 (12) 8 (11) 5 (15) 2 (13)
 Ongoing treatment 6 (5) 3 (4) 2 (5) 1 (6)
 In relation to radiotherapy 8 (5) 4 (5) 3 (8) 1 (6)
 Number of plasma glucose measurements, 
median (IQR)
9 (8–20) 8 (7–12) 13 (8–28) 30 (18–33)
 Number of plasma glucose measurements until 
time of diagnosis, median (IQR)
6 (3–8) 7 (4–15)
 Family history of diabetes (%)* 35 (27) 18 (24)
N = 73
12 (30)
N = 39
5 (31)
 Previous diabetes (glucocorticoid-induced or 
gestational)
1 (0.8) 1 (1.3) 0 0 
*N indicates numbers of patients with data.
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was 51% (95% CI: 42–61), the positive predictive value was 
19% (95% CI: 9–29) and the negative predictive value was 
96% (95% CI: 92–100). A total of 56 patients (43%) had an 
HbA1c value below the cut-off value.
Other risk factors
In univariate analysis, baseline PS and baseline triglyceride 
levels were positively associated with developing insulin-
treated DM. In the multivariate analyses, only baseline 
HbA1c remained statistically significantly associated with 
developing insulin-treated DM. Odds ratio of developing 
insulin-treated DM per 1 mmol/mol change in HbA1c was 
1.2 (1.04–1.3; P = 0.012) (Table 2).
Discussion
In this prospective observational study in cancer patients 
receiving high-dose glucocorticoids, 43% of the patients 
developed DM and 12% needed treatment with insulin to 
control glucose levels. Only one small prospective study 
with high-dose glucocorticoid treatment has previously 
been published (13). In that study of 35 patients with 
haematological diseases treated with at least 1 mg/kg/day of 
prednisolone 40.6% had developed DM at eight weeks (the 
definition of DM was fasting plasma glucose ≥7 mmol/L 
and/or postprandial plasma glucose ≥11.1 mmol/L). No 
patients needed antidiabetic treatment. The plasma glucose 
monitoring was less intensive than that in our study with 
only four measurements every week for 8 or 12  weeks. 
In a retrospective survey of 80 patients with lymphoma 
treated with prednisolone 100 mg/day for 5 days in each 
chemotherapy cycle, 32.5% developed glucocorticoid-
induced DM and 3.75% was treated with insulin (ADA 
definition of DM: fasting plasma glucose ≥7.0 mmol/L, 
random plasma glucose level ≥11.1 mmol/L accompanied 
by classical symptoms of hyperglycaemia). The intensity 
of plasma glucose measurements is not reported in the 
paper (14). The higher incidence of insulin-treated DM in 
our cohort may be explained by the closer monitoring of 
plasma glucose, a higher glucocorticoid dose, characteristics 
of the cohort and differences in clinical practice regarding 
treatment of glucocorticoid-induced DM. It is important to 
stress that the results of this study cannot be extrapolated 
to patients treated with substantially lower doses of 
glucocorticoids and to other patient types.
The finding that the majority of patients in our study 
needing insulin treatment were diagnosed within 7 days 
supports that glucocorticoid-induced DM develops rapidly. 
In accordance, a study with high-dose glucocorticoid 
treatment reported that 65.4% of the patients who 
developed DM were diagnosed during the first cycle of 
chemotherapy (14). Similarly, Fong et al. found that 94% 
of 69 non-diabetic patients with malignant and non-
malignant disease developed hyperglycaemia within the 
first 48 h of treatment with medium dose glucocorticoids 
(prednisone 25 mg/day) (15). In contrast, in studies with 
lower doses of glucocorticoid, DM developed throughout 
the entire treatment period (13, 14, 16, 17). This might be 
due to the monitoring practice with low-dose treatment 
where plasma glucose measurements are separated by 
many months.
The majority of patients who developed DM could 
probably have been identified within a few days if the 
screening had been even more thorough during the day. 
Figure 2
Time course of development of diabetes.
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Figure 3
Plasma glucose measurements throughout the day in patients not 
developing diabetes, patients developing untreated diabetes and 
patients developing diabetes treated with insulin.
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At any time of the day – also during fasting – the glucose 
values seemed to be higher in the group of patients 
needing insulin. However, there was a substantial overlap 
of fasting glucose levels in the three groups making 
it difficult to use fasting glucose as a predictor for the 
trajectory of the glucose pattern for the rest of the day. 
Continuous subcutaneous glucose measurements may 
further elucidate the glucose profiles among patients with 
glucocorticoid-induced DM.
In multivariate analyses, we found HbA1c to be 
the only risk factor for developing DM after initiation 
of high-dose glucocorticoid treatment. A similar result 
was reported in a retrospective study on 128 patients 
with rheumatic or renal disease receiving pulse therapy 
with high-dose glucocorticoid (methylprednisolone 
500–1000 mg/day for 3 days). In that study, odds ratio for 
developing glucocorticoid-induced DM when HbA1c was 
above or equal to 6% (42 mmol/mol), was 3.05 (18). In a 
retrospective survey of 80 patients with lymphoma treated 
with 100 mg/day prednisone as part of chemotherapy in 
cycles of 5  days, it was reported that patients with an 
HbA1c level >6.1% (43 mmol/mol) had a hazard ratio of 
9.35 for developing glucocorticoid-induced DM (15). We 
found that an HbA1c-value below 39 mmol/mol (which is 
the American Diabetes Association cut-off for prediabetes) 
was associated with a negative predictive value of 96% 
not to develop DM needing treatment with insulin. 
Applying this cut-off for further monitoring would in 
this population imply that we only had to screen half 
of our population with daily glucose measurements. It 
is not known if this cut-off value is applicable to other 
patient groups treated with glucocorticoids, since the 
negative predictive value depends on the prevalence of 
glucocorticoid-induced DM in a particular population. 
However, in similar populations measuring HbA1c before 
initiating high-dose glucocorticoid therapy may provide 
information about the risk of developing DM. It should, 
however, be kept in mind that erythrocyte turnover may 
be affected in cancer patients, for instance by the disease, 
by the chemotherapy or by blood transfusion, and this 
may hamper HbA1c interpretation.
Risk factors found in other studies of glucocorticoid-
induced DM are age and BMI (5, 13, 14, 18, 19). Additional 
risk factors proposed are dose of glucocorticoid (5, 20), 
family history of DM (13, 20) and hypertension (13). In our 
study population, we did not find age, BMI, hypertension 
or a family history of DM to be associated with developing 
DM. The reason for this is unclear. It was not possible to 
assess prednisolone dose as a risk factor in our study as the 
dose was almost similar in all patients.
Table 2 Univariate and multivariate logistic regression analyses with insulin-treated diabetes as dependent variable in 131 
patients without known diabetes suffering from MSCC and treated with ≥100 mg prednisolone per day.
 
 
Odds ratio of developing insulin-treated diabetes per  
change in explanatory variable
Univariate P Multivariate P
Variable
 Female sex 0.6 (0.2–1.9) 0.39 0.56 (0.13–2.7) 0.50
 Age (years) 1.0 (1.0–1.1) 0.59 0.99 (0.92–1.1) 0.72
 HbA1c at baseline (mmol/L) 1.2 (1.2–1.3) 0.001 1.2 (1.04–1.3) 0.012
 Daily dose of prednisolone (mg) 1.0 (1.0–1.0) 0.92 – –
 Having a parent or sibling with diabetes 1.2 (0.4–3.9) 0.71 1.1 (0.22–5.5) 0.92
 BMI at baseline (kg/m2) 1.0 (0.9–1.1) 0.92 1.0 (0.90–1.2) 0.71
 Dyslipidaemia 0.51 (0.11–2.4) 0.40 – –
 Hypertension 0.90 (0.31–2.6) 0.85 – –
 Atherosclerosis 1.7 (0.42–6.6) 0.47 – –
 Smoking 0.59 (0.20–1.7) 0.32 – –
 Alcohol abuse 0.90 (0.25–3.3) 0.88 – –
 Triglycerides (mmol/L) 1.8 (1.02–3.3) 0.045 1.1 (0.54–2.4) 0.72
 Total cholesterol (mmol/L) 1.3 (0.97–1.9) 0.08 – –
 Low-density lipoprotein (mmol/L) 1.4 (0.94–2.0) 0.10 – –
 High-density lipoprotein (mmol/L) 0.41 (0.13–1.3) 0.13 – –
 C-reactive protein (mg/L) 1.0 (0.99–1.0) 0.43 – –
 C-peptide (nmol/L) 1.0 (1.0–1.0) 0.32 – –
 Performance status (0–3) 2.1 (1.1–4.0) 0.028 2.1 (0.90–5.0) 0.09
Odds ratio (95% confidence intervals) of traditional risk factors for type 2 diabetes and other variables (explanatory variables) in univariate and 
multivariate logistic regression models with corticosteroid-induced insulin-treated diabetes as dependent variable. Established risk factors for type 2 
diabetes (sex, age, HbA1c, BMI, having a parent or sibling with diabetes) and variables from the univariate analysis with a P < 0.15 (only one of four lipid 
variables was chosen, since these variables are correlated) were included in the multivariate analysis.
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Strengths and limitations
Our prospective design allowed us to gather information 
of possible risk factors for DM, collect blood samples 
and take the medical history. Moreover, we included 
the number of patients predicted from our sample size 
calculation and found that the incidence of DM (43%) 
was higher than expected. Hence, we regard the statistical 
power of the study satisfactory. Compared to other 
studies, the plasma glucose monitoring intensity in the 
present study is a strength. However, we may still have 
misclassified some patients as non-diabetic, especially if 
glucose measurements were done in the morning or were 
very few. Therefore, the number of patients developing 
DM in our study should be regarded as a conservative 
estimate. Moreover, classification of patients as needing 
treatment with insulin was not guideline-driven but based 
on the decision according to local practice. Hence, the 
classification of patients reflects everyday clinical practice 
and in many settings no strict rules for antidiabetic 
treatment of glucocorticoid-induced hyperglycemia exist.
Conclusions
In our study, a substantial proportion of the patients 
developed insulin-treated DM as a result of high-dose 
glucocorticoid therapy. Glucocorticoid-induced DM may, 
if left untreated, cause substantial morbidity. Therefore, 
screening for hyperglycaemia before and during treatment 
with glucocorticoids is rational.
However, at present, there is no consensus about 
a screening strategy. The American Endocrine Society 
Clinical Practice Guideline (7) recommends laboratory 
blood glucose testing on admission for all inpatients and 
continued testing for patients receiving glucocorticoid 
therapy. If all blood glucose results are below 7.8 mmol/L 
for a period of at least 24–48 h the testing may be 
discontinued. The Joint British Diabetes Societies for 
inpatient care, JBDS-IP recommends HbA1c testing prior 
to commencement of glucocorticoid treatment in patients 
perceived to be at high risk (not defined) of glucocorticoid-
induced DM and subsequent blood glucose monitoring at 
least once daily in the afternoon or evening when plasma 
glucose values are highest (6).
Our data on patients with MSCC challenge these 
guidelines in different ways. Firstly, HbA1c testing in 
all patients will identify half of the patients as high-
risk patients (HbA1C ≥39 mmol/mol) who need further 
monitoring and half of the patients as low-risk patients 
who can be spared continued blood glucose testing. 
Secondly, we identified the majority of patients who 
needed insulin treatment to control blood glucose within 
the first week and had the testing been stopped within 
24–48 h some might have been missed.
We suggest a two-step screening procedure using an 
initial HbA1c measurement to identify high-risk patients 
to be followed with glucose measurements. This approach 
warrants prospective testing in other cohorts.
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